GlaxoSmithKline (GSK) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS

GlaxoSmithKline (NYSE:GSK) released its earnings results on Wednesday. The pharmaceutical company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.69 by $0.03, Morningstar.com reports. GlaxoSmithKline had a net margin of 7.79% and a return on equity of 115.30%. The business had revenue of $10.14 billion during the quarter, compared to analyst estimates of $9.89 billion.

Shares of GlaxoSmithKline (GSK) traded up $0.68 during trading hours on Thursday, hitting $36.71. 5,310,933 shares of the company traded hands, compared to its average volume of 5,207,722. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. The stock has a market cap of $91,350.00, a P/E ratio of 42.45, a PEG ratio of 2.31 and a beta of 0.98. GlaxoSmithKline has a fifty-two week low of $34.52 and a fifty-two week high of $44.53.

Large investors have recently modified their holdings of the stock. Field & Main Bank purchased a new stake in shares of GlaxoSmithKline in the 4th quarter valued at approximately $132,000. First Dallas Securities Inc. acquired a new position in GlaxoSmithKline in the 4th quarter valued at approximately $142,000. Wealthcare Advisory Partners LLC increased its stake in GlaxoSmithKline by 1,982.8% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock valued at $143,000 after buying an additional 3,351 shares during the period. Quadrant Capital Group LLC increased its stake in GlaxoSmithKline by 3.5% in the 2nd quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after buying an additional 148 shares during the period. Finally, Advisory Services Network LLC increased its stake in GlaxoSmithKline by 24.2% in the 2nd quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock valued at $175,000 after buying an additional 788 shares during the period. Institutional investors and hedge funds own 9.66% of the company’s stock.

Several research firms recently commented on GSK. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Monday. ValuEngine downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Wednesday, January 17th. Barclays upgraded shares of GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 16th. Finally, UBS Group restated a “buy” rating on shares of GlaxoSmithKline in a research report on Monday, January 15th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the company’s stock. GlaxoSmithKline has an average rating of “Hold” and a consensus price target of $38.57.

ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline (GSK) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.com-unik.info/2018/02/08/glaxosmithkline-gsk-issues-quarterly-earnings-results-beats-expectations-by-0-03-eps.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Earnings History for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit